Poseida Therapeutics (CDMO)

San Diego, CA
Find alternatives to Poseida Therapeutics (CDMO) for CAR-T →
Hybrid — also manufactures internal programs
6 confirmed programs · 1 sponsors · Last scored 2026-10-29
58.7
Signal Score
○ FDA Inspections ✓ Clinical Trials (6) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Poseida Therapeutics (CDMO)

Signal Score
58.7/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
San Diego, CA
Modalities
CAR-T, Cell Therapy, Gene Editing
Active Programs
6 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Poseida Therapeutics (CDMO)

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 51.7
6 active programs across 1 sponsors
Modalities: CAR-T, Gene Editing, Cell Therapy
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
6 active programs across 1 sponsors · Modalities: CAR-T, Gene Editing, Cell Therapy · 1 programs in advanced phases (Phase 2/3)
Programs 6
Sponsors1
ModalitiesCAR-T, Cell Therapy, Gene Editing
6 active programs across 1 sponsors
Modalities: CAR-T, Gene Editing, Cell Therapy
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06014762 P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Active Not Recruiting
NCT04960579 P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Active Not Recruiting
NCT05239143 P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Active Not Recruiting
NCT04249947 P-PSMA-101 CAR-T Cells in the Treatment of Subjects With... PHASE1 Terminated
NCT03741127 Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 PHASE1 Active Not Recruiting
NCT03288493 P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With... PHASE1/PHASE2 Terminated
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 68.0
Parent company: Roche
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Roche
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: San Diego, CA
Modalities: CAR-T, Cell Therapy, Gene Editing
Capacity assessment: 58.0/100
Sites: San Diego, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: San Diego, CA
Modalities: CAR-T, Cell Therapy, Gene Editing
Capacity assessment: 58.0/100

Hiring Activity 3 open roles Beta

From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
3
open roles
3
in manufacturing, quality, PD/MSAT, engineering or regulatory (100%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 214 taken down.
By function
Quality (QA / QC) 1
Process development & MSAT 2
By site
San Diego profile site
· 1 QA/QC · 2 PD/MSAT
3
Latest postings
Principal Quality Systems Specialist Quality (QA / QC) · San Diego
Scientist 3, Nucleic Acids Payload Engineering Process development & MSAT · San Diego
Scientist 3 Process development & MSAT · San Diego
Coverage: read from the parent company's careers board and kept only postings at this business's sites (San Diego site on the Genentech board). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: roche.wd3.myworkdayjobs.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Frequently Asked Questions About Poseida Therapeutics (CDMO)

How many clinical programs is Poseida Therapeutics (CDMO) linked to?
Poseida Therapeutics (CDMO) is associated with 6 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Poseida Therapeutics (CDMO)'s CDMO Signal Score?
Poseida Therapeutics (CDMO) has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Poseida Therapeutics (CDMO) for a manufacturing program?
Use the free AI matchmaker to compare Poseida Therapeutics (CDMO) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs → Gene Editing CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 79.3
CAR-T, Cell Therapy, iPSC, Gene Editing
GenScript
Piscataway, NJ / Nanjing, China
Signal Score: 64.0
CAR-T, Cell Therapy, Gene Editing
CTMC
Houston, TX
Signal Score: 63.0
CAR-T, Cell Therapy, Gene Editing
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy

Compare Poseida Therapeutics (CDMO) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Poseida Therapeutics (CDMO)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.